Guardant Health, Inc. — Form 8-K
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Guardant Health reported Q2 2026 revenue of $335.0M (up 44% YoY), driven by Oncology revenue of $219.1M (up 38%, 104k tests up 63%) and Screening revenue of $52.9M (up 257%, 66k tests from 16k YoY). Company raised FY2026 revenue guidance to $1.34–$1.36B (up from $1.30–$1.32B), with Screening revenue now expected $218–230M (270k–285k tests) and Oncology volume growth raised to ~50% (from ~35%). Non-GAAP gross margin improved to 67% (from 66%). However, GAAP net loss widened to $120.1M vs. $99.9M YoY, and free cash flow burn increased to $(69.5)M vs. $(65.9)M YoY; FY2026 free cash flow guidance worsened to $(195–205)M burn (from prior $(185–195)M).
Why this rating
44% revenue growth and raised guidance are material for a $6.2B company (~$335M quarterly revenue = 5% of market cap annualized). Shield (Screening) growth >250%, Oncology acceleration, and FDA approvals validate strategic position. However, accelerating cash burn and widening net losses offset gains; company remains unprofitable at scale.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.